Interview with a company that has settled in Bejiing, China explains why...cost is one issue coming in at one third the amount required here in the United States...and another is the availability of scientists...we all think cost is the only area that drives business overseas, but this is another added benefit according to the article...they are hungry and have one big thirst for knowledge...an area where we lag behind a bit, just look at how slow the average person accepts and uses technology here as a simple example...shortly there could be more English speaking folks in China as they are using the Internet to learn English too...the company recently attracted one of the senior scientists from Merck, who will live here but travel and coordinate efforts...contracts are still negotiated in the US, but much of the actual work goes on overseas...BD 
John Oyler has founded a string of startups in the US, including Genta, a biotech specializing in cancer drug discovery, and Galenea, which focuses on treatments for psychiatric diseases. But in 2005 he chose China as his base to launch BioDuro, a life sciences Contract Research Organisation (CRO). He explains to Chemistry World how he has managed to turn BioDuro into one of China's leading CROs in just three years.
By the end of this year, we will have nearly 600 chemists and biologists working for the company. Most of the world's top pharmaceutical firms are our clients. We have our business and marketing headquarters in San Diego, California. We have a team of more than 20 senior scientists leading the firm, many of whom used to be at multinationals like Merck and Pfizer.
0 comments :
Post a Comment